Spatial omics in cancer: decoding tumor heterogeneity, metabolic reprogramming and therapy resistance

Tumors are spatially organized ecosystems in which malignant cells, immune cells, stromal cells, vasculature, extracellular matrix and metabolites interact within structured tissue niches. Bulk RNA sequencing has clarified cancer-associated molecular programmes, and single-cell RNA sequencing has resolved cellular heterogeneity, but both approaches incompletely preserve the anatomical relationships that govern invasion, immune escape, metabolic competition and therapy resistance. Spatial omics addresses this gap by linking molecular measurements to tissue coordinates, histology and cellular neighbourhoods. In cancer research, spatial transcriptomics, spatial proteomics, multiplexed imaging and spatial metabolomics now allow investigators to resolve tumor heterogeneity across RNA, protein and metabolic layers. This review summarizes the technological landscape of spatial multi-omics and synthesizes its application to tumor microenvironment mapping, cell-cell communication, tertiary lymphoid structures, clonal evolution, metabolic reprogramming and treatment resistance. Particular emphasis is placed on spatial metabolic vulnerabilities, including lipid metabolism, amino acid competition, ferroptosis-associated states and pharmacological distribution within tumor tissue. We further discuss how spatial biomarkers, spatial pharmacokinetics and spatial pharmacodynamics may improve patient stratification and guide rational combination therapy. The field is moving from descriptive tissue mapping toward mechanism-driven, clinically interpretable spatial oncology. Its translational value will depend on robust multimodal integration, functional validation, standardized tissue workflows and collaboration among oncology, pathology, bioinformatics, pharmacology and engineering.

Authors

Institutions

Publication Details

Journal
Frontiers in Cell and Developmental Biology
Published
2026-11-13
DOI
https://doi.org/10.3389/fcell.2026.1949072
Primary Topic
Single-cell and spatial transcriptomics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Spatial omics in cancer: decoding tumor heterogeneity, metabolic reprogramming and therapy resistance

Yanpin Ma, Hudabia Akram, Wenjuan Chen, Ziyi Xu et al.
3 links
Frontiers in Cell and Developmental Biology
Single-cell and spatial transcriptomics
article

Spatial omics in cancer: decoding tumor heterogeneity, metabolic reprogramming and therapy resistance

Yanpin Ma, Hudabia Akram, Wenjuan Chen, Ziyi Xu, Xinyu Gu
article en

Abstract

Tumors are spatially organized ecosystems in which malignant cells, immune cells, stromal cells, vasculature, extracellular matrix and metabolites interact within structured tissue niches. Bulk RNA sequencing has clarified cancer-associated molecular programmes, and single-cell RNA sequencing has resolved cellular heterogeneity, but both approaches incompletely preserve the anatomical relationships that govern invasion, immune escape, metabolic competition and therapy resistance. Spatial omics addresses this gap by linking molecular measurements to tissue coordinates, histology and cellular neighbourhoods. In cancer research, spatial transcriptomics, spatial proteomics, multiplexed imaging and spatial metabolomics now allow investigators to resolve tumor heterogeneity across RNA, protein and metabolic layers. This review summarizes the technological landscape of spatial multi-omics and synthesizes its application to tumor microenvironment mapping, cell-cell communication, tertiary lymphoid structures, clonal evolution, metabolic reprogramming and treatment resistance. Particular emphasis is placed on spatial metabolic vulnerabilities, including lipid metabolism, amino acid competition, ferroptosis-associated states and pharmacological distribution within tumor tissue. We further discuss how spatial biomarkers, spatial pharmacokinetics and spatial pharmacodynamics may improve patient stratification and guide rational combination therapy. The field is moving from descriptive tissue mapping toward mechanism-driven, clinically interpretable spatial oncology. Its translational value will depend on robust multimodal integration, functional validation, standardized tissue workflows and collaboration among oncology, pathology, bioinformatics, pharmacology and engineering.

Frontiers in Cell and Developmental BiologyVol. 14
Henan University of Science and Technology (CN), First Affiliated Hospital of Henan University of Science and Technology (CN)
Good health and well-being
Single-cell and spatial transcriptomics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon